阿里健康(00241.HK)涨近8%创上市新高 获中信证券重申增持
中信证券认为政策明显利好互联网医疗,相信阿里健康(00241.HK)可把握医疗数字化新基建机遇加速发展,公司也可望借助医药电商板块优势,延伸互联网医疗生态,故重申阿里健康「增持」评级。该股今天突破上月所创上市高位21.5元,最高见22.8元,现造22.1元,续升7.8%,成交急增至8,514万股,涉资18.7亿元。富时罗素将於下周一(22日)正式把阿里健康纳入富时中国50指数。
同系自愿於新加坡交易所除牌的阿里影业(01060.HK)今天一举突破20天、百天线及10天线(1.02-1.06元),最高见1.1元,现造1.08元,回升8%,成交急增至9,800万股,涉资1.048亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.